Clincosm LogoSign in Get a demo

Study of the Inflammatory Microenvironment in Atypical Meningiomas

Sponsor
Central Hospital, Nancy, France (Other)
Overall Status
Recruiting
CT.gov ID
NCT04761653
Collaborator
(none)
84
Enrollment
1
Location
5.9
Anticipated Duration (Months)
14.2
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Atypical meningiomas represent 15% of meningiomas. They present a high rate of recurrence, and therapeutic strategies are limited. There is a need for novel treatment strategies, such as immuotherapy.

This is a retrospective study including 84 patients with primary diagnosis of atypical meningiomas. The presence of T cells (CD4, CD8, Treg and memory T cells) and mature dendritic cells will be quantified on whole tissue sections stained by immunohistochemistry (CD4, CD8, FOXP3, CD45RO and CD208).

This could allow us to identify novel biomarkers for survival, and facilitate the selection of patients who may benefit from immunotherapeutic modalities.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    84 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Prognostic Impact of the Inflammatory Microenvironment in Atypical Meningiomas
    Actual Study Start Date :
    Jan 1, 2021
    Anticipated Primary Completion Date :
    Jun 30, 2021
    Anticipated Study Completion Date :
    Jun 30, 2021

    Outcome Measures

    Primary Outcome Measures

    1. Progression free survival [2-21 years]

    Secondary Outcome Measures

    1. Overall survival [2-21 years]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • primary diagnosis of atypical meningioma

    • surgery

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Guillaume GAUCHOTTE Vandoeuvre Les Nancy France 54511

    Sponsors and Collaborators

    • Central Hospital, Nancy, France

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Guillaume GAUCHOTTE, PU PH, Central Hospital, Nancy, France
    ClinicalTrials.gov Identifier:
    NCT04761653
    Other Study ID Numbers:
    • 2021PI015
    First Posted:
    Feb 21, 2021
    Last Update Posted:
    Feb 21, 2021
    Last Verified:
    Feb 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Meningioma

    Study Results

    No Results Posted as of Feb 21, 2021